3728 Jinke Rd, Building 1, West Wing, Shanghai, China
info@tyligand.com
Tyligand Bioscience to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Shanghai, Jan 14th, 2025 - Tyligand Bioscience, a clinical-stage biotechnology company dedicated to developing innovative therapeutics against drug resistant tumors, today announced that Tony Zhang, Ph.D., the company’s Chief Executive Officer and Co-founder, will deliver a corporate presentation as part of the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, Jan 16th, 2025 at 1:15 p.m. PST in San Francisco.
Tyligand Bioscience is a clinical-stage biotech company founded in 2017, focusing on the discovery and development of innovative cancer therapeutics. The company commenced business operations in 2018. Leveraging decades of profound experience in leading drug discovery and development at multinational pharmaceutical companies, the management team has successfully established technology platforms with fully integrated capabilities across small molecules and antibody-drug conjugates (ADCs). Serving as an innovation engine, these platforms have enabled the company to build a diversified pipeline encompassing multiple drug candidates.
Consistently driven by the mission to address significant unmet clinical needs, Tyligand Bioscience is dedicated to becoming a leading global biopharmaceutical enterprise. By continuously delivering high-quality, differentiated innovative therapies, the company aims to improve the quality of life for patients worldwide and create long-term commercial value.
For more info about Tyligand Bioscience, please visit www.tyligand.com
- Tyligand Bioscience